Prion Diseases

Slide 1 · Prion Diseases

Molecular propagation · spongiform pathology · clinicopathologic correlation

Pathology teaching lecture

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

After this lecture, learners should be able to:

Explain how altered PrP conformation initiates self-propagating pathology.

Distinguish sporadic, inherited and acquired prion disease.

Recognize the hallmark microscopic findings and explain their diagnostic significance.

Connect prion biology with the principal clinical CJD patterns.

Slide 3 · Prion disease: Three defining dimensions

Prion disease combines a molecular mechanism, a characteristic lesion and a clinical syndrome.

Molecular

Misfolded prion protein

Propagation to other PrP molecules

Morphologic

Spongiform gray-matter change

PrP deposition

Clinical

Progressive neurologic decline

Rapid dementia in typical CJD

Slide 4 · What makes a prion disease?

A pathogenic protein can acquire properties usually associated with transmissible agents.

The fundamental lesion is aggregation of misfolded prion protein (PrP).

Abnormal PrP can facilitate conversion of additional normal PrP molecules.

Prion disorders can originate without an exposure event.

Transmission is one route of initiation—not a universal requirement.

Slide 5 · The disease process at one glance

Different initiators ultimately converge on a common protein-propagation pathway.

Initiation

Spontaneous event, PRNP-related predisposition or acquired PrP

Conversion

Abnormal PrPˢᶜ recruits PrPᶜ

Aggregation

Abnormal PrP accumulates in brain

Injury

Spongiform change and neuronal degeneration

Slide 6 · Why prion disorders are neurodegenerative

They belong in the proteinopathy framework of nervous-system disease.

Loss of selected neuronal populations produces clinical dysfunction.

Misfolded proteins accumulate in abnormal conformations.

Deposits are unusually resistant to proteolytic clearance.

Prion diseases illustrate protein propagation more directly than most other proteinopathies.

Slide 7 · Human disorders associated with PrP

The source classifies these as human prion diseases.

Creutzfeldt–Jakob disease

Sporadic, inherited or acquired forms

Rapidly progressive dementia

Inherited syndromes

Gerstmann–Sträussler–Scheinker syndrome

Fatal familial insomnia

Historically transmitted

Kuru

Propagation after exposure

Slide 8 · Prion disorders also occur in animals

The same protein-misfolding principle extends beyond human disease.

Small ruminants

Scrapie

Sheep and goats

Wild cervids

Chronic wasting disease

Deer and elk

Other mammals

Bovine spongiform encephalopathy

Mink-transmissible encephalopathy

Slide 9 · Three origins, one pathological process

Classification by origin explains how the first abnormal PrP molecule appears.

Sporadic

Rare spontaneous conformational change

No inherited mutation or exposure needed

Inherited

PRNP mutation predisposes conversion

Germline molecular susceptibility

Acquired

Introduction of abnormal PrP

Transmissible disease process

Slide 10 · The core biochemical substrate is PrP

The prion protein, rather than a conventional pathogen, is central to disease.

Normal cellular prion protein is designated PrPᶜ.

PrP as approximately 30 kDa; Its normal function is uncertain.

Pathogenesis depends on a conformational change of this protein.

The disease-associated isoform is conventionally called PrPˢᶜ.

Do not infer normal PrP function from the disease phenotype.

Slide 11 · Normal and disease-associated PrP differ in folding

A change in three-dimensional conformation changes protein behavior.

Property

PrPᶜ: normal form

PrPˢᶜ: disease-associated form

Secondary structure

Relatively α-helix–rich

Relatively β-sheet–rich

Proteolysis

More susceptible

Increased resistance

Behavior

No pathological templating described

Promotes conversion of PrPᶜ

Tissue pathology

Not the disease hallmark

Aggregates in affected brain

Slide 12 · A conformational change is the initiating event

Altered folding—not necessarily an altered amino-acid sequence—defines the abnormal isoform.

PrPᶜ

Native α-helix–enriched fold

Transition

Conformational rearrangement

PrPˢᶜ

β-sheet–enriched form

Propagation

Newly formed PrPˢᶜ acts as template

Slide 13 · Mutation is not necessary in every case

Sporadic disease separates protein conversion from a required change in DNA sequence.

PrPᶜ can very rarely shift spontaneously into a disease-associated conformation.

A germline PRNP mutation increases susceptibility in inherited forms.

Once generated, the abnormal PrP conformer propagates independently of the initial trigger.

The same convergent process explains sporadic, familial and acquired cases.

Slide 14 · Sporadic initiation: An exceptional molecular event

Sporadic CJD to conversion occurring at a very low spontaneous rate.

Normal PrPᶜ

Usual cellular protein population

Rare event

Spontaneous abnormal folding

PrPˢᶜ

First disease-associated seed

Amplification

Conversion of additional PrPᶜ

Slide 15 · Inherited initiation: Genetic predisposition

Germline PRNP mutations can favor emergence of the abnormal conformation.

PRNP variant

Inherited change in prion protein gene

Susceptibility

Higher PrPᶜ→PrPˢᶜ conversion rate

Seed formation

Initial abnormal conformer

Propagation

Sustained PrPˢᶜ accumulation

Slide 16 · Acquired initiation: An exogenous seed

Exposure can introduce PrPˢᶜ, which then recruits host PrPᶜ.

Exposure

Transmissible pathological material

Entry

Disease-associated PrP reaches host

Templating

Host PrPᶜ converted

Amplification

Abnormal PrP burden increases

Slide 17 · PRNP connects molecular mechanism to inherited disease

The gene encodes PrP, linking genotype to protein folding.

Mutations in PRNP cause hereditary prion disease phenotypes.

Familial CJD is one PRNP-associated presentation.

Gerstmann–Sträussler–Scheinker syndrome and fatal familial insomnia are also linked.

Do not equate PRNP mutation with iatrogenic or sporadic disease.

Slide 18 · Templated conversion is central to propagation

Existing PrPˢᶜ promotes formation of more PrPˢᶜ through interaction with PrPᶜ.

An abnormal conformer interacts with the normally folded protein.

That interaction promotes acquisition of the pathological fold.

The newly converted molecule can recruit further PrPᶜ.

This enables spreading molecular pathology without requiring a replicating microbe.

Slide 19 · Prion multiplication is conformational amplification

The molecular population expands by host-protein conversion.

Seed

A small amount of PrPˢᶜ

Recruit

Contact with PrPᶜ

Convert

Additional PrPˢᶜ forms

Amplify

More templates now available

Slide 20 · Initiation, propagation and aggregation are different steps

Keeping the phases distinct improves causal interpretation.

Initiation

Origin of first abnormal conformer

Can be sporadic, genetic or transmitted

Propagation

Recruitment and conversion of PrPᶜ

Explains spreading pathology

Aggregation

Build-up of misfolded protein

Associated with cellular damage

Slide 21 · Intercellular movement extends the process

Spreading of disease-associated protein aggregates between cells.

Propagation can take place within an affected nervous system.

A seeded protein-folding process links one affected cell to others.

Cell-to-cell spreading is a bridge to hypotheses in other neurodegenerative diseases.

True transmissibility to another individual remains a distinct epidemiologic phenomenon.

Slide 22 · Misfolding ultimately produces tissue pathology

Accumulation of abnormal PrP is linked to neuronal dysfunction and degeneration.

PrPˢᶜ

Misfolded protein

Build-up

Tissue aggregates accumulate

Cell injury

Neuronal/glial dysfunction

Tissue lesion

Spongiform change and neuronal loss

Slide 23 · The detailed mechanism of neuronal death remains uncertain

The source explicitly distinguishes observed pathology from an unresolved causal step.

Accumulation of PrPˢᶜ appears to drive the neurodegenerative process.

Neuronal and glial vacuoles are characteristic findings.

Precisely how abnormal PrP creates vacuoles and kills neurons is not established in the source.

Teaching diagrams should not insert an unverified molecular toxicity pathway.

Evidence supports association and amplification; It does not resolve every intermediate cellular event.

Slide 24 · Proteinase K separates two PrP behaviors

Partial proteolysis is exploited to identify disease-associated protein.

Laboratory feature

PrPᶜ

PrPˢᶜ

Protein conformation

Normal cellular fold

Abnormal β-sheet–rich fold

Proteinase K exposure

Relatively digested

Partly resistant

After controlled digestion

Reduced residual antigen

Persistent abnormal PrP antigen

Diagnostic implication

Not a specific disease signal

Supports prion-disease tissue detection

Slide 25 · Why controlled proteolysis helps tissue diagnosis

The order of specimen processing matters conceptually.

Tissue

Contains PrP species

Partial digestion

Proteinase K removes susceptible material

Immunostain

Detect remaining PrP antigen

Interpret

Protease-resistant PrPˢᶜ signal

Slide 26 · PrP immunostaining detects the abnormal protein

Post-digestion PrP immunostaining as diagnostic.

Partially digest tissue with proteinase K before PrP staining.

Residual protease-resistant PrP is the disease-associated target.

The staining establishes a molecular correlate of the spongiform lesion.

The result must be interpreted in the morphologic and clinicopathologic setting.

Slide 27 · Protein deposition and neuron damage are distinct observations

An immunostain and a routine morphology stain answer different questions.

PrP immunoreactivity demonstrates abnormal protein deposition.

H&E sections reveal neuropil vacuoles and neuronal loss.

The two findings are complementary rather than interchangeable.

Neither method should be represented by an invented microscopic image.

Slide 28 · From molecular process to diagnostic evidence

Three levels connect pathogenesis with pathological interpretation.

Mechanism

Conformational conversion

Biochemical propagation

Tissue signature

Spongiform vacuolation

Neuronal loss / gliosis

Protein signature

Protease-resistant PrP

Immunostaining after digestion

Slide 29 · Spongiform change is the defining microscopic pattern

The hallmark is tissue vacuolation that creates a sponge-like appearance.

Small clear spaces arise within neural tissue.

Cerebral cortex and deep gray matter are typically affected in CJD.

Vacuolation can be multifocal and uneven in distribution.

Microscopic change may be conspicuous even when the brain shows little atrophy.

Slide 30 · Schematic of spongiform vacuolation

Recognize the topologic pattern; This drawing is not a histology image.

Schematic — not histology

Pattern to recognize

Multiple clear vacuoles

Different vacuole sizes

Vacuoles within neuropil

Neuronal injury in advanced lesions

Slide 31 · Gray-matter structures are especially involved

The source emphasizes cortex and deep nuclear gray matter in CJD.

Cerebral cortex often shows widespread microscopic involvement.

Caudate and putamen are examples of affected deep gray-matter regions.

Distribution may be patchy, not uniformly destructive.

The anatomic pattern helps connect microscopic injury with cognitive and neurologic decline.

Slide 32 · Where do the small clear spaces appear?

Histologic vacuoles may be seen in more than one compartment.

Neuropil

Vacuoles within the extracellular-looking neural meshwork

Produced by intracellular vacuolation in neuronal processes

Neurons

Perikaryal vacuoles may occur

Neuronal profiles can be affected

Glia

Glial vacuolation contributes

The process involves neural tissue compartments

Slide 33 · Electron microscopy localizes vacuoles to cell processes

Ultrastructural evidence clarifies the apparently empty spaces.

Vacuoles appear membrane-bound on electron microscopy.

They are located within the cytoplasm of neuronal processes.

Thus the light-microscopic sponge-like appearance reflects cellular pathology.

This distinction is important when interpreting schematic representations.

Slide 34 · Progression of the tissue lesion

Morphology becomes more destructive as disease advances.

Early change

Small dispersed vacuoles

Established

Conspicuous spongiform neuropil

Progression

Neuronal loss and reactive gliosis

Advanced

Confluent enlarged cyst-like spaces

Slide 35 · Neuronal loss accompanies advanced disease

Vacuolation is not the only consequence of PrP accumulation.

Advanced lesions show marked depletion of neurons.

Loss of neurons contributes to neurologic deterioration.

Reactive gliosis occurs in affected tissue.

Severe vacuolated areas may expand into status spongiosus.

Slide 36 · Reactive gliosis indicates a response to injury

Glial reaction accompanies degenerating nervous tissue.

Gliosis is part of advanced prion-disease morphology.

It occurs with neuronal loss and neuropil change.

This reactive response is not equivalent to a substantial inflammatory infiltrate.

Report gliosis and inflammation as separate morphologic observations.

Slide 37 · The absence of inflammation is diagnostically striking

Prion disease can show severe tissue injury without conspicuous inflammation.

Feature

Characteristic prion finding

Interpretive significance

Spongiform change

Multifocal neuropil vacuoles

Signature architectural alteration

Neuronal loss

May be severe

True tissue degeneration

Gliosis

Reactive glial response

Response to neural injury

Inflammation

Notably absent

Distinct from inflammatory encephalitis pattern

Slide 38 · Gross atrophy may be surprisingly limited

The rapid clinical course can outpace dramatic macroscopic brain shrinkage.

Typical CJD often progresses before major visible atrophy develops.

Gross examination may therefore underestimate severity.

Microscopic evaluation remains crucial.

Longer-surviving cases may show extensive gray-matter atrophy.

Slide 39 · Kuru plaques represent extracellular PrP aggregates

Not every prion lesion is simply an empty vacuole.

Kuru plaques consist of aggregated disease-associated PrP.

They are extracellular deposits.

The classic source describes prominent cerebellar occurrence.

Variant CJD can show numerous plaques in cerebral cortex.

Slide 40 · Kuru plaques have recognizable staining properties

The plaque is a protein aggregate visible using established histologic stains.

Observation

Finding

Why it matters

Location

Extracellular deposit

Different from intracellular vacuoles

Material

Aggregated PrPˢᶜ

Links morphology to proteinopathy

PAS stain

Positive

Provides histochemical visualization

Congo red

Positive

Consistent with amyloid-like aggregate

Slide 41 · Plaque distribution differs across prion phenotypes

Morphology can vary despite the shared molecular substrate.

Kuru

Cerebellar plaque prominence

Deposits of aggregated PrP

Classic CJD

Spongiform change dominates

Plaques are not required in every case

Variant CJD

Numerous cortical plaques

Often associated with surrounding spongiform change

Slide 42 · Schematic of vacuoles near a protein deposit

The conceptual field separates vacuolation from aggregated PrP deposition.

PrP aggregate

Schematic — not histology

Two different lesions

Vacuoles alter the neuropil

Protein deposits reflect PrP aggregation

Both can coexist in one field

Confirm with authentic H&E and PrP staining

Slide 43 · The core microscopic reporting vocabulary

Each item describes a distinct morphologic observation.

Term

What it denotes

Relationship to pathology

Spongiform change

Multiple small vacuoles

Architectural signature

Status spongiosus

Large confluent vacuolated spaces

Advanced degeneration

Neuronal loss

Fewer surviving neurons

Destructive component

Gliosis

Reactive glial changes

Tissue response

PrP deposit

Abnormal protein accumulation

Molecular hallmark

Slide 44 · Rapidly progressive dementia anchors typical CJD

Neurologic deterioration is usually much faster than in many common degenerative dementias.

CJD often begins with subtle cognitive or behavioral change.

A rapidly progressive dementing syndrome soon develops.

Additional motor and cerebellar signs support the clinical pattern.

The rapid course reflects aggressive neuronal pathology.

Slide 45 · Early manifestations may be subtle

The initial period can precede obvious global cognitive decline.

Patients may first show changes in memory.

Behavioral change can be an early complaint.

These features are nonspecific in isolation.

Subsequent rapid progression changes their diagnostic significance.

Slide 46 · Startle myoclonus is a characteristic clinical clue

Abrupt involuntary contractions may appear when patients are suddenly stimulated.

Myoclonus means brief, shock-like involuntary muscle jerks.

The source emphasizes a startle-related form in CJD.

Its association with rapidly worsening dementia is suggestive.

It is a clinical clue, not by itself a protein-specific test.

Slide 47 · Ataxia reflects cerebellar dysfunction

A subset of patients develop impaired coordination during the illness.

Cerebellar involvement may produce an ataxic gait or limb incoordination.

Cerebellar signs in a minority of typical CJD cases.

The exact mix of neurologic deficits varies.

The clinical syndrome should be interpreted with the overall tempo of disease.

Slide 48 · Typical clinical trajectory in CJD

The sequence illustrates progression, not a fixed timetable for every patient.

Early

Memory or behavior change

Acceleration

Progressively worsening cognition

Associated signs

Myoclonus, sometimes ataxia

Advanced

Severe disability and death

Slide 49 · Sporadic CJD is the dominant form

The textbook provides a useful epidemiologic scale for classic CJD.

The sporadic form accounts for over 90% of CJD cases.

The annual incidence is approximately 1 per million persons.

Peak incidence is reported in the seventh decade.

These source estimates should not be generalized to every prion phenotype.

Slide 50 · Inherited prion disorders have distinct names

PRNP mutation can yield several recognized human syndromes.

Familial CJD is one inherited prion disease.

Gerstmann–Sträussler–Scheinker syndrome is another.

Fatal familial insomnia is also classified in the PRNP-associated group.

Shared PrP propagation does not imply identical clinical presentation.

Slide 51 · Iatrogenic CJD has documented exposure routes

Transmission has been associated with specific historical medical materials and procedures.

Transplanted tissue

Corneal transplantation

Dural grafts

Instrumentation

Deep implantation of brain electrodes

Contamination of invasive equipment

Biologic preparations

Cadaveric human growth hormone

Contaminated preparations

Slide 52 · Classic CJD is uniformly fatal in the cited source

Its clinical severity is reflected in survival after symptom onset.

Typical CJD as a fatal disorder.

Average survival in the cited text is approximately seven months after onset.

A minority of cases survive several years.

Longer survival can permit pronounced macroscopic gray-matter atrophy.

Slide 53 · Variant CJD was clinically recognizable as a different syndrome

The 1990s UK presentations differed from classic sporadic CJD.

Age

More often young adults

Unlike typical late-life sporadic CJD

Initial syndrome

Behavioral changes prominently early

Psychiatric/behavioral presentation

Tempo

Slower progression than classic CJD

Still progressive neurodegeneration

Slide 54 · BSE exposure was linked to variant CJD

Evidence linking the human disorder to bovine spongiform encephalopathy.

BSE

Prion disease in cattle

Food exposure

Contaminated bovine products

Human exposure

Acquired abnormal PrP

VCJD

Distinct human phenotype

Slide 55 · Blood transmission matters for variant CJD

The source notes transmission through blood from persons without overt symptoms.

VCJD was also linked to transfusion of blood from infected donors.

Transmission could occur during the asymptomatic or preclinical phase.

Clinical absence of symptoms is not equivalent to absence of transmission risk.

This observation motivated public health safeguards.

Slide 56 · Classic and variant CJD should not be conflated

Differences in presentation and pathology matter even with a shared PrP mechanism.

Feature

Classic sporadic CJD

Variant CJD

Typical age

Later life; peak seventh decade

Young adults prominent

Early clinical change

Memory/behavior then dementia

Behavioral symptoms often early

Tempo

Rapid deterioration

Relatively slower course

Pathology

Spongiform gray matter lesions

Abundant cortical kuru-type plaques

Exposure link

Usually sporadic

Associated with BSE

Slide 57 · Public health measures changed the vCJD epidemic

Recognition of the BSE–vCJD link had actionable consequences.

VCJD emerged in the United Kingdom in the 1990s.

Its UK incidence peaked around 2000 in the Robbins account.

Measures to limit transmission were followed by a marked decline.

The association illustrates why prion biology has population-level relevance.

Slide 58 · Shared mechanism does not mean a uniform phenotype

Origin, clinical expression and anatomical involvement should be reported separately.

Different human prion syndromes arise through a common PrP process.

Phenotype may vary among sporadic, genetic and transmitted forms.

Classic CJD and vCJD illustrate clinically distinct patterns.

Mechanistic classification and clinicopathologic classification answer different questions.

Slide 59 · A source-grounded tissue interpretation pathway

Morphology and abnormal-protein evidence are complementary.

Clinical suspicion

Rapid decline with suggestive neurologic features

H&E morphology

Spongiform change ± neuronal loss

PrP method

Proteinase K step + immunostain

Integration

Prion disease tissue diagnosis

Slide 60 · Recognize what this source does not specify

Do not silently substitute newer tests or diagnostic criteria into textbook-derived content.

The supplied section emphasizes morphology and tissue PrP immunostaining.

It does not detail contemporary CSF-based tests, imaging criteria or surveillance case definitions.

No sensitivity, specificity or diagnostic threshold can be inferred here.

Definitive clinical testing algorithms require separately verified contemporary sources.

Slide 61 · Application: Rapidly progressive dementia

An older adult develops subtle memory changes followed by rapidly worsening dementia and stimulus-sensitive involuntary jerks. A brain sample shows widespread gray-matter vacuoles and little inflammation.

Interpretation task

Identify the most likely disease family.

Which molecular event explains the pathology?

Slide 62 · Case reasoning: Clinical and morphologic convergence

The findings are characteristic of a classical prion-disease pattern.

Rapid dementia with myoclonus is suggestive of CJD.

Spongiform change with little inflammation supports a prion process.

PrPᶜ-to-PrPˢᶜ conversion explains self-amplifying molecular pathology.

Proteinase-resistant PrP tissue staining provides the cited molecular correlate.

Slide 63 · Application: New behavioral symptoms after exposure

A young adult develops prominent early behavioral changes and a gradually progressive neurologic illness. Historical exposure to products associated with bovine spongiform encephalopathy is reported.

Interpretation task

Which CJD phenotype deserves consideration?

What would distinguish its typical brain pathology?

Slide 64 · Case reasoning: Variant CJD pattern

Age, behavior, tempo and exposure suggest a variant phenotype.

Younger age and early behavioral symptoms support a vCJD pattern.

A slower course than classic CJD is consistent with the source.

Numerous cortical kuru-type plaques are a characteristic morphologic clue.

The case is hypothetical and does not establish a diagnosis without evaluation.

Slide 65 · Prion disease versus other proteinopathies

The parent section connects prion propagation to wider neurodegeneration.

Prion disorders

PrPˢᶜ deposits

Protein conversion is directly transmissible

Alzheimer disease

Aβ plaques and tau tangles

Different disease-associated proteins

Parkinson disease

α-Synuclein aggregates

Different clinical-anatomic pattern

Slide 66 · Established findings versus unanswered questions

Accurate teaching should show the current evidentiary boundary of the supplied source.

Established

PrP conformational conversion

Protease resistance; Tissue deposits

Described association

PrP accumulation with vacuolation

Neuronal loss and gliosis

Not resolved here

Detailed mechanism of vacuole formation

Exact steps causing neuron death

Slide 67 · Unified model of prion pathobiology

The central model connects disease origin, protein change and clinicopathologic effects.

Origin

Sporadic / inherited / acquired

Protein change

PrPᶜ → PrPˢᶜ

Propagation

Templating and aggregation

Tissue disease

Spongiform lesions / neurodegeneration

Molecular and morphologic evidence should be integrated.

Slide 68 · Consolidation: Five conclusions

Prion diseases are defined by a distinctive molecular propagation mechanism.

PrP misfolding can begin spontaneously, genetically or after exposure.

PrPˢᶜ converts further PrPᶜ and resists protease digestion.

Spongiform change is the signature lesion; Gliosis and neuronal loss accumulate.

Classic CJD and vCJD differ clinically and morphologically.

The proximal mechanism of neuronal toxicity remains incompletely explained.

Slide 69 · References and evidence boundary

Primary teaching source: Robbins, Cotran & Kumar, Pathologic Basis of Disease, 11th ed. (2026).

Chapter 28, “Neurodegenerative Diseases” and “Prion Diseases,” pp. 1159–1161.

Relevant adjacent sections: “Creutzfeldt-Jakob Disease,” “Variant Creutzfeldt-Jakob Disease,” and Morphology.

Source diagrams are original native-PowerPoint schematics; no textbook histology images are reproduced.

The original chapter PDF was not supplied; the textbook Markdown conversion was checked for adjacent context, not against page images.